

For internal distribution only

February 6, 2025

Medicare Part D Benefit Coverage Change

As a part of our due diligence to inform all concerned of Medicare Part D Formulary Changes, the following notification is requested by CMS to be sent to all Providers.

Medicare Part D Benefit Coverage – Product removal

Product(s) Removal: Humira (2 SYRINGE) PSKT 20 MG/0.2 ML

Effective March 1, 2025, the brand-name drug **Humira (2 SYRINGE) PSKT 20 MG/0.2 ML** will be removed from our Drug List. We will add a new biosimilar of the original biological product to the Drug List (it is called adalimumab-adaz SOSY 20 MG/0.2ML).

Affected members who were prescribed these drugs prior to each effective date will continue to receive the removed product under their Part D benefit until 12/31/2025, except for members who have been converted to the generic or biosimilar alternatives.

The following table lists all the changes for the 2025 year so far.

Reason for change	Drug Name/Description	Date and Type of Change:	Alternate Drug (Note: Over-the-counter (OTC) drugs are not covered under the Medicare Part D benefit)
Biosimilar Available	HUMIRA (2 SYRINGE) PSKT 20 MG/0.2ML	March 1, 2025 Original biological product to be replaced with biosimilar	ADALIMUMAB-ADAZ SOSY 20 MG/0.2ML
Generic Available	SPRYCEL TABS 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, 140 MG	February 1, 2025 Brand drug to be replaced with generic	DASATINIB TABS 20 MG, 50 MG, 70 MG, 80 MG, 100 MG, 140 MG
Generic Available	LUCEMYRA TABS 0.18 MG	February 1, 2025 Brand drug to be replaced with generic	LOFEXIDINE HCL TABS 0.18 MG
Biosimilar Available	HUMIRA (2 SYRINGE) PSKT 40 MG/0.4ML	February 1, 2025 Original biologic to be replaced with biosimilar	SIMLANDI (2 SYRINGE) PSKT 40 MG/0.4ML